Theravance Biopharma, Inc. is a high-risk Pharmaceuticals company based in the United States of America. They focus on developing organ-selective medicines to address patient needs in the areas of inflammation and immunology. Their ESG score is 30.4, reflecting their commitment to sustainability and governance. Specializing in lung-selective medicines, their product YUPELRI is FDA-approved for COPD treatment.